22nd Century Group and KeyGene Launch Advanced Cannabis Technology Platform for Accelerated Development of New Varieties of Hemp/Cannabis Plants with Commercially Valuable Traits

Breakthrough expected to yield disruptive plant lines and new licensing opportunities with strategic partners WILLIAMSVILLE, N.Y., Feb. 10, 2021 (GLOBE NEWSWIRE) — 22nd Century Group, Inc. (NYSE American: XXII), a leading plant-based, biotechnology company focused on tobacco harm reduction, very low nicotine content tobacco, and hemp/cannabis research, announced today that it has developed and launched… Continue reading 22nd Century Group and KeyGene Launch Advanced Cannabis Technology Platform for Accelerated Development of New Varieties of Hemp/Cannabis Plants with Commercially Valuable Traits

22nd Century Group to Relocate Headquarters to Buffalo’s Thriving Larkinville District

New space is ideally equipped and located in the heart of Buffalo’s urban renewal WILLIAMSVILLE, N.Y., Jan. 28, 2021 (GLOBE NEWSWIRE) — 22nd Century Group, Inc. (NYSE American: XXII), a leading plant-based, biotechnology company that is focused on tobacco harm reduction, very low nicotine content tobacco, and hemp/cannabis research, announced today that the Company is… Continue reading 22nd Century Group to Relocate Headquarters to Buffalo’s Thriving Larkinville District

The Buffalo News Op-ed: 22nd Century CEO Urges FDA to Proceed with Plan to Limit Nicotine Levels in Cigarettes

The FDA Can Save 8 Million Lives and Prevent 1,600 Kids From Becoming Addicted Every Day WILLIAMSVILLE, N.Y., Jan. 26, 2021 (GLOBE NEWSWIRE) — 22nd Century Group, Inc., a leading plant-based, biotechnology company that is focused on tobacco harm reduction, very low nicotine content tobacco, and hemp/cannabis research, announced today that the Buffalo News, the… Continue reading The Buffalo News Op-ed: 22nd Century CEO Urges FDA to Proceed with Plan to Limit Nicotine Levels in Cigarettes

22nd Century Group Expands VLN® Tobacco Growing Program to Support Anticipated Demand of the Company’s Reduced Nicotine Content Cigarettes

Company will significantly increase planting in the 2021 crop year WILLIAMSVILLE, N.Y., Jan. 12, 2021 (GLOBE NEWSWIRE) — 22nd Century Group, Inc. (NYSE American: XXII), a leading plant-based, biotechnology company that is focused on tobacco harm reduction, very low nicotine content tobacco, and hemp/cannabis research, announced today that the Company will significantly expand its growing… Continue reading 22nd Century Group Expands VLN® Tobacco Growing Program to Support Anticipated Demand of the Company’s Reduced Nicotine Content Cigarettes

22nd Century Group Expands VLN® Tobacco Growing Program to Support Anticipated Demand of the Company’s Reduced Nicotine Content Cigarettes

Company will significantly increase planting in the 2021 crop year WILLIAMSVILLE, N.Y., Jan. 11, 2021 (GLOBE NEWSWIRE) — 22nd Century Group, Inc. (NYSE American: XXII), a leading plant-based, biotechnology company that is focused on tobacco harm reduction, very low nicotine content tobacco, and hemp/cannabis research, announced today that the Company will significantly expand its growing… Continue reading 22nd Century Group Expands VLN® Tobacco Growing Program to Support Anticipated Demand of the Company’s Reduced Nicotine Content Cigarettes

22nd Century Group Achieves Breakthrough Hemp/Cannabis GMO Technology; Granted New Patent for Controlling Genes Responsible for Production of CBD, THC, and Other Valuable Cannabinoids

New intellectual property facilitates the precise control and modulation of cannabinoid production WILLIAMSVILLE, N.Y., Dec. 17, 2020 (GLOBE NEWSWIRE) — 22nd Century Group, Inc. (NYSE American: XXII), a leading plant-based, biotechnology company focused on tobacco harm reduction, very low nicotine content tobacco, and hemp/cannabis research, announced today that it was granted a new U.S. patent… Continue reading 22nd Century Group Achieves Breakthrough Hemp/Cannabis GMO Technology; Granted New Patent for Controlling Genes Responsible for Production of CBD, THC, and Other Valuable Cannabinoids

22nd Century Receives Order for 3.6 Million New SPECTRUM® Variable Nicotine Cigarettes for U.S. Government-Supported Research

The Company’s Research Cigarettes Continue to Fuel Studies Adding to the Vast Body of Research Supporting a National Nicotine Standard for Combustible Cigarettes WILLIAMSVILLE, N.Y., Dec. 08, 2020 (GLOBE NEWSWIRE) — 22nd Century Group, Inc. (NYSE American: XXII), a leading plant-based, biotechnology company that is focused on tobacco harm reduction, announced today that the U.S. Food… Continue reading 22nd Century Receives Order for 3.6 Million New SPECTRUM® Variable Nicotine Cigarettes for U.S. Government-Supported Research

22nd Century Group to Present at 13th Annual LD Micro Main Event Conference

WILLIAMSVILLE, N.Y., Dec. 04, 2020 (GLOBE NEWSWIRE) — 22nd Century Group, Inc. (NYSE American: XXII), a leading plant-based, biotechnology company that is focused on tobacco harm reduction, very low nicotine content tobacco, and hemp/cannabis research, announced today that it will be presenting at the 13th Annual LD Micro Main Event Conference on Monday, December 14,… Continue reading 22nd Century Group to Present at 13th Annual LD Micro Main Event Conference

22nd Century’s Vice President of Regulatory Science Publishes Important Public Policy Article

Article Urges the FDA to Accelerate Implementation of its Plan to Limit Nicotine Levels in All Cigarettes and to Provide Less Harmful Alternatives for Smokers of Highly Addictive Cigarettes WILLIAMSVILLE, N.Y., Nov. 24, 2020 (GLOBE NEWSWIRE) — 22nd Century Group, Inc. (NYSE American: XXII), a leading plant-based, biotechnology company that is focused on tobacco harm… Continue reading 22nd Century’s Vice President of Regulatory Science Publishes Important Public Policy Article

22nd Century’s Vice President of Regulatory Science Publishes Important Public Policy Article

Article Urges the FDA to Accelerate Implementation of its Plan to Limit Nicotine Levels in All Cigarettes and to Provide Less Harmful Alternatives for Smokers of Highly Addictive Cigarettes WILLIAMSVILLE, N.Y., Nov. 24, 2020 (GLOBE NEWSWIRE) — 22nd Century Group, Inc. (NYSE American: XXII), a leading plant-based, biotechnology company that is focused on tobacco harm… Continue reading 22nd Century’s Vice President of Regulatory Science Publishes Important Public Policy Article